Manufacturer
DUOPHARMA (M) SDN. BHD.
Contents
Dexamethasone Na phosphate
Indication
Inflammatory joint diseases, Shock, Diabetic macular oedema, Macular oedema secondary to retinal vein occlusion, Uveitis, Cerebral oedema caused by malignancy, Anti-inflammatory or immunosuppressive.
Instruction
Administer via slow IV injection, Intra-articular, Intravitreal and parenteral.
Drug interaction
Decreased plasma concentration with CYP3A4 inducers (e.g. barbiturates, carbamazepine, ephedrine, phenytoin, rifabutin, rifampicin). Increased plasma concentration with CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, ritonavir). May increase renal clearance of salicylates. May enhances hypokalaemic effects of diuretics (acetazolamide, loop, thiazide), amphotericin B injection, corticosteroids, carbenoxolone, and K-depleting agents. May enhance anticoagulant effect of warfarin.Potentially Fatal: May diminish therapeutic effect of live virus vaccines.
Malaysia
